Abstract Number: 1985 • ACR Convergence 2020
Validity and Reliability of Four Parent/Patient Reported Outcome Measures for Juvenile Idiopathic Arthritis
Background/Purpose: In the last years, the interest in the assessment of parent- and child-reported outcomes (PCROs) in paediatric rheumatic diseases is gaining increasing importance. These…Abstract Number: 1986 • ACR Convergence 2020
Determinants of Variation in Pediatric Systemic Lupus Erythematosus Care Delivery
Background/Purpose: Patients with pediatric systemic lupus erythematosus (pSLE) receive only a fraction of recommended care. Moreover, variation in care delivery likely contributes to pervasive racial…Abstract Number: 1987 • ACR Convergence 2020
Predictors of Adverse Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus Transitioning to Adult Care
Background/Purpose: The transition from pediatric to adult care is a vulnerable period and is linked to increased healthcare utilization and poor outcomes. We sought to…Abstract Number: 1988 • ACR Convergence 2020
Skin Disease More Recalcitrant to Intervention Than Muscle Disease: A Long-Term Prospective Study of 184 Children with Juvenile Dermatomyositis
Background/Purpose: Persistent skin manifestations, in particular calcinosis, contribute to significant morbidity in patients with JDM. The goal of this study was to compare the course…Abstract Number: 1989 • ACR Convergence 2020
NXP2 Autoantibodies Link to Interferon Signature in Juvenile Myositis Lesional Skin
Background/Purpose: Skin inflammation can herald systemic disease in juvenile myositis (JM), yet we lack an understanding of pathogenic mechanisms driving skin inflammation in JM. The…Abstract Number: 1990 • ACR Convergence 2020
Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…Abstract Number: 1991 • ACR Convergence 2020
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…Abstract Number: 1992 • ACR Convergence 2020
Longitudinal Evaluation of Axonal Dysfunction, Neuronal Markers and Serum Cytokines in Childhood-onset Systemic Lupus Erythematosus
Background/Purpose: To analyze 1H-MRS brain metabolites in a longitudinal study and to determine clinical, laboratory and treatment features associated with its occurrence. To determine, additionally…Abstract Number: 1993 • ACR Convergence 2020
Cardiovascular Risk in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for cardiovascular (CV) events. While most RA patients use conventional disease-modifying antirheumatic drugs (DMARDs) such as…Abstract Number: 1994 • ACR Convergence 2020
Rheumatoid Arthritis Improvement After Exposure to an Anti-Inflammatory “ITIS” Diet Is Associated with Changes of Gut Microbiome and Systemic Metabolome
Background/Purpose: A new dimension has been added to the link between diet and health, the gut microbiome. Of particular interest is the influence of diet…Abstract Number: 1995 • ACR Convergence 2020
Non-invasive Vagus Nerve Stimulation Improves Signs and Symptoms of Rheumatoid Arthritis: Results of a Pilot Study
Background/Purpose: Vagus nerve stimulation (VNS) has been shown to improve rheumatoid arthritis (RA) disease severity in patients with refractory disease (1,2). A multi-center pilot study…Abstract Number: 1996 • ACR Convergence 2020
Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study
Background/Purpose: Pneumococcal vaccination is recommended in patients with RA who are receiving conventional synthetic/biologic DMARDs.1 Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to…Abstract Number: 1997 • ACR Convergence 2020
Immunogenicity of Adjuvanted Herpes Zoster Subunit Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors and Controls: Preliminary Results
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of contracting herpes zoster (HZ) and treatment with JAnus Kinase inhibitors (JAKi) further adds on…Abstract Number: 1998 • ACR Convergence 2020
Ten-year Analysis of the Risk of Severe Outcomes Related to Very Low-dose Glucocorticoids in Early Rheumatoid Arthritis
Background/Purpose: Although glucocorticoids (GC) remain an essential part of the therapeutic strategy in Rheumatoid Arthritis (RA), the long-term risk of adverse events of low-dose GC…Abstract Number: 1999 • ACR Convergence 2020
Hydroxychloroquine Is Not Cardiotoxic in Patients with Rheumatoid Arthritis
Background/Purpose: Hydroxychloroquine (HCQ) has been proposed as a potential treatment for COVID-19, but early reports suggested that it could have cardiotoxic effects. Despite widespread and…
- « Previous Page
- 1
- …
- 785
- 786
- 787
- 788
- 789
- …
- 2425
- Next Page »